TRAIL及其受体与卵巢恶性肿瘤的研究进展  

Recent advances of research on ovarian carcinoma of TRAIL and its receptor

作　　者：鲁大伟[1] 杨宏英[1] 

机构地区：[1]昆明医学院第三附属医院(云南省肿瘤医院)妇瘤科,云南昆明650031

出　　处：《现代肿瘤医学》2012年第6期1281-1285,共5页Journal of Modern Oncology

基　　金：云南省卫生厅科技处资助项目(编号:2009NS019)

摘　　要：肿瘤坏死因子相关的凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)是最近发现的TNF家族的新成员,TRAIL有两类受体,一类是死亡受体,诱导肿瘤细胞或转化细胞凋亡,另一类是"诱骗"受体,保护正常细胞免遭TRAIL的诱导凋亡作用。卵巢癌患者经几个疗程化疗后,常对化疗药产生多药耐药现象,从而使化疗失败,最终导致肿瘤复发和转移。TRAIL和化疗药联合应用能逆转卵巢癌细胞的多药耐药性(multidrug resistance)。本文就TRAIL、TRAIL受体(TRAILR)表达及TRAIL的凋亡途径等在卵巢恶性肿瘤治疗中的应用做一全面综述。Tumor necrosis factor related apoptosis inducing ligand（TRAIL） is the new member of tumor necrosis factor family.TRAIL have two types of receptors,one is death receptor,induce tumor cell apoptosis,another is decoy receptor,protect normal cells from TRAIL of apoptosis.After several times of chemotherapy,the patients of ovarian carcinoma will have multidrug resistance which induce fail of chemotherapy.TRAIL and chemotherapy combined application can reverse multidrug resistance of ovarian cancer cells.This article reviews the TRAIL,TRAILR expression and TRAIL apoptosis way in the treatment of ovarian carcinoma.

关 键 词：TRAIL TRAIL受体 细胞凋亡 卵巢恶性肿瘤 

分 类 号：R737.31[医药卫生—肿瘤]